Lilly’s AI commitment expands through deal with Insilico

Eli Lilly expands AI-driven drug discovery through a partnership with Hong Kong-based Insilico. The agreement covers development and commercialization of experimental preclinical drugs, strengthening Lilly's commitment to leveraging artificial intelligence for accelerating pharmaceutical innovation and bringing new treatments to market faster.